ClinicalTrials.gg
RecruitingNCT06883097QMHUpdated Sep 30, 2026

Quitting Matters Human Immunodeficiency Virus Hybrid Trial

An interventional study of Learn to Quit-HIV (LTQ-H) App and QuitStart in Tobacco, Tobacco Abstinence and Smoking Cessation, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.
Updated Sep 30, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
314
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 920 studies in Smoking Cessation with a site in United States — 98 open to participants now, 126 under way, 7 of them phase 3. Smoking Cessation · United States.

Planned enrollment
296th of 872
314 · median 149
Started
2025
with 27 others
No phase
512 of 920
68 open now
Primary completion
2028-09
later than 105 of 125 live
Registered
866th of 920
by date

Among the 920 studies in Smoking Cessation with a site in United States, this one is the 296th largest by planned enrollment of the 872 interventional ones that give a count, is one of 28 that started in 2025, is one of 512 with no phase, reaches primary completion later than 105 of the 125 other live ones, and was the 866th registered.

Smoking Cessation

1,582 studies on the registry are indexed under Smoking Cessation; 198 are open to participants now.

Browse Smoking Cessation studies →

Open to participants now

98 of the 920 studies in Smoking Cessation with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 137 Smoking Cessation studies recruiting now, 93 (68%) set no upper age limit and 37 (27%) stop at 75 or younger; 6 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 920 studies in Smoking Cessation with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare the advantages and disadvantages of two approaches for quitting smoking among people living with HIV (PWH). Participants will complete a 24- week (\~6-month) study where the Participants will be assigned to one of two smartphone apps to help with quitting smoking. Regardless of the group participants are assigned to, they will also receive a combination of nicotine replacement therapy (patches and gums) that have been shown to help people quit smoking. The main questions this study aims to answer are:

Participants will complete 6 video call visits over about 6 months. Participants will install their assigned smoking cessation app onto their phone and will be asked to use the app for the duration of the study along with their provided Nicotine Replacement Therapy (NRT) products. During the study visits, participants will meet with study staff to complete questionnaires and interviews. Participants may be asked to provide breath and saliva samples to measure the level of carbon monoxide and nicotine.

Read the detailed description

Tobacco use has alarmingly high rates among people with Human Immunodeficiency Virus (HIV) (PWH), 43% compared with 15% in the general population. Due to the development of highly effective treatments for HIV and the resulting increased longevity among PWH, this population now loses more life years to smoking than to HIV infection itself. Novel and effective models to deliver wider reaching smoking cessation interventions for PWH are highly needed and indicated as a priority for National Institute of Health. Digital therapeutics (DTx) may be a novel, scalable, and highly available approach for engaging and treating smoking in this population. However, although DTx for smoking cessation have been shown effective in the general population, no large trial to date has examined the effectiveness of a tailored DTx for smoking cessation in PWH, and no implementation science work has examined barriers and facilitators of implementation of DTx for smoking cessation in this population.

03

Conditions studied

  • Tobacco
  • Tobacco Abstinence
  • Smoking Cessation
  • Smoking Cessation; Tobacco Dependence
  • Human Immunodeficiency Virus (HIV)
  • Tobacco Dependence Caused by Cigarettes
  • Cancer Prevention

Keywords

  • Tobacco
  • Smoking Cessation
  • Human immunodeficiency virus (HIV)
  • Tobacco Abstinence
  • Quit Smoking
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Self-reported daily cigarette smoking over the past 30 days
  2. Self-reported status
  3. Age 18 or older
  4. Desire to quit smoking
  5. Willing and medically eligible to use NRT
  6. Currently receiving HIV care
  7. Currently owning an Android or iOS smartphone

Exclusion criteria

Exclusion Criteria:

  1. Current acute psychotic episode or unsafe to participate in the study
  2. Pregnant or intending to become pregnant in the next 6 months
  3. Currently receiving any pharmacological and/or behavioral intervention or counseling for smoking cessation
  4. Any medical condition or medication that could compromise subject safety, as determined by the PIs and/or study physician
  5. Not able to fluently speak and write in English
  6. Hearing, comprehension, visual, speech, or motor limitations that preclude study participation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
314 participants (estimated)

Study arms

  • Experimental
    Learn to Quit - HIV (LTQ-H) App

    a smoking cessation Digital Therapeutic (DTx) for people with HIV (PWH)

    Behavioral: Learn to Quit-HIV (LTQ-H) App

  • Active comparator
    QuitStart App

    an evidence-based DTx designed for the general population

    Behavioral: QuitStart

Interventions

  • BehavioralLearn to Quit-HIV (LTQ-H) App

    LTQ-H consists of 319 screens divided into: (a) HIV-tailored smoking cessation ACT skills, (b) education about tobacco dependence and treatment (USCPG), and (c) NRT psychoeducation and adherence. Content is gradually presented across 28 modules (14 education and 14 skills) that can be completed in 14 days.

    Also known as: a smoking cessation Digital Therapeutic (DTx)

  • BehavioralQuitStart

    This DTx, QuitGuide was adapted from the National Cancer Institute Smokefree.gov Initiative's QuitGuide's 5 modules have the following intervention components: (a) psychoeducation about the impact of smoking on health, (b) setting up a quit date and a quit plan, (c) selecting reasons for quitting, (d) tracking triggers and smoking habits, and (e) tips for quitting.

    Also known as: an evidence-based DTx designed for the general population

06

What researchers measure

Primary outcomes

  1. Biochemically verified 7-day point prevalence abstinence at 6, 12, 18, and 24-weeks

    Abstinence is determined by a self-report of not smoking any cigarettes for greater than or equal to 7 days prior to Weeks 6, 12, 18, and 24 and biochemically verified by an expired carbon monoxide breath test or a cotinine level saliva test at Weeks 6, 12, 18, and 24. Criteria for the bioverification tests to be considered abstinent includes a reading of \<6 parts per million using an iCOquit Smokerlyzer carbon monoxide breath test OR a cotinine level of 30 or less ng/ml using an iScreen saliva test. If the participant does not meet both criteria of the self report of 7 or more days of abstinence plus a bioverification test below the thresholds listed above, they are not considered abstinent. As per convention, participants are assumed to be smoking if they report smoking at the time-point, cannot be reached to provide data at the time-point, fail to provide a breath sample at the time-point, or provide a breath sample at the time-point that is greater than or equal to 6 ppm.

    Time frame: Weeks 6, 12, 18, and 24

Secondary outcomes

  1. Self-reported 7-day point prevalence abstinence at 6 weeks - the percentage of participants who are abstinent from cigarettes at a given point in time

    Percent of subjects in each group self-reporting no smoking at all for greater or equal to 7 days prior to the timepoint.

    Time frame: 6 weeks

  2. Self-reported 7-day point prevalence abstinence at 12 weeks - the percentage of participants who are abstinent from cigarettes at a given point in time

    Percent of subjects in each group self-reporting no smoking at all for greater or equal to 7 days prior to the timepoint.

    Time frame: 12 weeks

  3. Self-reported 7-day point prevalence abstinence at 18 weeks - the percentage of participants who are abstinent from cigarettes at a given point in time

    Percent of subjects in each group self-reporting no smoking at all for greater or equal to 7 days prior to the timepoint.

    Time frame: 18 weeks

  4. Self-reported 7-day point prevalence abstinence at 24 weeks - the percentage of participants who are abstinent from cigarettes at a given point in time

    Percent of subjects in each group self-reporting no smoking at all for greater or equal to 7 days prior to the timepoint.

    Time frame: 24 weeks

  5. Self-reported 30-day point prevalence abstinence at 6 weeks - the percentage of participants who are abstinent from cigarettes at a given point in time

    Percent of subjects in each group self-reporting no smoking at all for greater or equal to 30 days but \< 30 days prior to the timepoint.

    Time frame: 6 weeks

  6. Self-reported 30-day point prevalence abstinence at 12 weeks - the percentage of participants who are abstinent from cigarettes at a given point in time

    Percent of subjects in each group self-reporting no smoking at all for greater or equal to 30 days prior to the timepoint.

    Time frame: 12 weeks

  7. Self-reported 30-day point prevalence abstinence at 18 weeks - the percentage of participants who are abstinent from cigarettes at a given point in time

    Percent of subjects in each group self-reporting no smoking at all for greater or equal to 30 days prior to the timepoint.

    Time frame: 18 weeks

  8. Self-reported 30-day point prevalence abstinence at 24 weeks - the percentage of participants who are abstinent from cigarettes at a given point in time

    Percent of subjects in each group self-reporting no smoking at all for greater or equal to 30 days prior to the timepoint.

    Time frame: 24 weeks

  9. Change in average number of cigarettes smoked per day

    Change in self-reported number of cigarettes smoked per day, averaged within groups.

    Time frame: 6 weeks

  10. Change in average number of cigarettes smoked per day

    Change in self-reported number of cigarettes smoked per day, averaged within groups.

    Time frame: 12 weeks

  11. Change in average number of cigarettes smoked per day

    Change in self-reported number of cigarettes smoked per day, averaged within groups.

    Time frame: 18 weeks

  12. Change in average number of cigarettes smoked per day

    Change in self-reported number of cigarettes smoked per day, averaged within groups.

    Time frame: 24 weeks

  13. Average number of quit attempts

    Average number of quit attempts self-reported per group at the specified time point. Quit attempts are defined by no smoking cigarettes at all for 24 hours or more.

    Time frame: 6 weeks

  14. Average number of quit attempts

    Average number of quit attempts self-reported per group at the specified time point. Quit attempts are defined by no smoking cigarettes at all for 24 hours or more.

    Time frame: 12 weeks

  15. Average number of quit attempts

    Average number of quit attempts self-reported per group at the specified time point. Quit attempts are defined by no smoking cigarettes at all for 24 hours or more.

    Time frame: 18 weeks

  16. Average number of quit attempts

    Average number of quit attempts self-reported per group at the specified time point. Quit attempts are defined by no smoking cigarettes at all for 24 hours or more.

    Time frame: 24 weeks

  17. Average acceptance of physical smoking cravings

    Average self-reported scores of acceptance of cravings on the physical sensations subscale of the Avoidance and Inflexibility Scale. Scores range from 4-20 with lower scores indicating more acceptance of smoking cravings.

    Time frame: 6 weeks

  18. Average acceptance of physical smoking cravings

    Average self-reported scores of acceptance of cravings on the physical sensations subscale of the Avoidance and Inflexibility Scale. Scores range from 4-20 with lower scores indicating more acceptance of smoking cravings.

    Time frame: 12 weeks

  19. Average acceptance of physical smoking cravings

    Average self-reported scores of acceptance of cravings on the physical sensations subscale of the Avoidance and Inflexibility Scale. Scores range from 4-20 with lower scores indicating more acceptance of smoking cravings.

    Time frame: 18 weeks

  20. Average acceptance of physical smoking cravings

    Average self-reported scores of acceptance of cravings on the physical sensations subscale of the Avoidance and Inflexibility Scale. Scores range from 4-20 with lower scores indicating more acceptance of smoking cravings.

    Time frame: 24 weeks

  21. Average frequency of app use

    Average frequency of app use over the 24-week study period. Measured by average number of app openings.

    Time frame: Weeks 0-24

  22. Average duration of app use

    Average duration of app use over the 24-week study period.

    Time frame: Weeks 0-24

  23. Average number of app modules completed

    Average number of app modules completed over the 24-week study period.

    Time frame: Weeks 0-24

07

Study locations

1 of 1 sites recruiting
  • Wake Forest University, Implementation Science
    Winston-Salem, North Carolina 27101, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Sep 2028, 37 months after the start.

Of 547 non-industry interventional studies with no phase under Smoking Cessation, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 45. This study's planned 37 months is above that.

Counting every sponsor, half of 564 studies reached it within 24 months; a quarter within 12 and three quarters within 44.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Dec 2028 → Sep 2028 and completion Dec 2028 → Sep 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Mar 19, 2025
StartActual
Aug 18, 2025
Primary completionEst.
Sep 2028was Dec 2028
CompletionEst.
Sep 2028was Dec 2028
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2028→Sep 2028
Sep 30, 2026
Study completion
Dec 2028→Sep 2028
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Primary completion Dec 2028→Sep 2028
    Study completion Dec 2028→Sep 2028
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06883097
Responsible party
Sponsor
First posted
Mar 19, 2025
Start date
Aug 18, 2025
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Roger Vilardaga Vierra, Ph.D.
Contact
Roger.Vilardaga@wfusm.edu
336-716-1495
Clinical Studies Coordinator
Contact
caitlyn.arnold@advocatehealth.org
(984) 377-4306
Roger Vilardaga Viera, Ph.D.
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion